Respiratory Syncytial Virus Pediatric Hospitalization in the COVID-19 Era

Int J Environ Res Public Health. 2022 Nov 22;19(23):15455. doi: 10.3390/ijerph192315455.

Abstract

Respiratory syncytial virus (RSV) globally affects the population, mainly young children, potentially causing hospitalization. During the COVID-19 pandemic, non-pharmacological measures interfered with the circulation of most respiratory viruses. Then, with the discontinuation of restrictive measures, a new scenario appeared. With this scoping review, we want to globally explore whether the RSV paediatric hospitalization rate was influenced by COVID-19. This scoping review was performed according to PRISMA guidelines on PubMed using the Mesh terms "Respiratory Syncytial Viruses"[Mesh] AND "COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh]. Among them, we identified studies pertaining to children and adolescents up to 18 years old hospitalized for RSV, including 18 records in the revision. With the onset of the COVID-19 pandemic, a drastic reduction in RSV hospitalization among the pediatric population in 2020-2021 season has been observed in the Northern and Southern hemispheres. After the relaxing of restrictive measures, unexpected outbreaks happened, leading to increased hospitalization and occupation of pediatric intensive care units.

Keywords: COVID-19; children; hospitalization; respiratory syncytial virus.

Publication types

  • Review

MeSH terms

  • Adolescent
  • COVID-19* / epidemiology
  • Child
  • Child, Preschool
  • Hospitalization
  • Humans
  • Infant
  • Pandemics
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Viruses

Grants and funding

This research received no external funding.